ZIOPHARM Oncology Company Profile (NASDAQ:ZIOP)

About ZIOPHARM Oncology

ZIOPHARM Oncology logoZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex. The Company's Ad-RTS-IL-12 + veledimex has been evaluated in two Phase II studies, the first for the treatment of metastatic melanoma, and the second for the treatment of unresectable recurrent or metastatic breast cancer. It has initiated the Phase I study for malignant glioma. The Company has completed the Phase II monotherapy studies in melanoma and breast cancer using Ad-RTS-IL-12 + veledimex. It has initiated a Phase Ib/II study of Ad-RTS-hIL-12 + veledimex following chemotherapy for the treatment of patients with locally metastatic breast cancer. Its initial drug candidate being developed using the synthetic immuno-oncology platform is Ad-RTS-IL-12 + veledimex.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ZIOP
  • CUSIP: 98973P10
Key Metrics:
  • Previous Close: $6.82
  • 50 Day Moving Average: $6.12
  • 200 Day Moving Average: $5.87
  • 52-Week Range: $4.45 - $9.74
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.41
  • P/E Growth: 0.00
  • Market Cap: $880.89M
  • Outstanding Shares: 130,496,000
  • Beta: 1.47
Profitability:
  • Net Margins: -2,276.89%
  • Return on Equity: -364.49%
  • Return on Assets: -32.89%
Debt:
  • Current Ratio: 7.35%
  • Quick Ratio: 7.35%
Additional Links:
Companies Related to ZIOPHARM Oncology:

Analyst Ratings

Consensus Ratings for ZIOPHARM Oncology (NASDAQ:ZIOP) (?)
Ratings Breakdown: 4 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $11.50 (85.19% upside)

Analysts' Ratings History for ZIOPHARM Oncology (NASDAQ:ZIOP)
Show:
DateFirmActionRatingPrice TargetDetails
2/10/2017Griffin SecuritiesReiterated RatingBuy$21.00 -> $23.00View Rating Details
1/12/2017J P Morgan Chase & CoReiterated RatingHoldView Rating Details
8/10/2016Wells Fargo & CompanyUpgradeUnderperform -> Market PerformView Rating Details
7/18/2016MizuhoReiterated RatingNeutral$7.00 -> $5.00View Rating Details
6/2/2016Raymond James Financial, Inc.Initiated CoverageMarket PerformView Rating Details
6/22/2015BMO Capital MarketsDowngradeOutperform -> Market Perform$15.00 -> $10.00View Rating Details
5/13/2015GuggenheimInitiated CoverageNeutralView Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for ZIOPHARM Oncology (NASDAQ:ZIOP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017        
11/9/2016Q3 2016($0.11)($0.11)$1.45 million$1.60 millionViewN/AView Earnings Details
8/9/2016Q216($0.11)($1.01)$1.52 million$1.70 millionViewN/AView Earnings Details
5/10/2016Q1($0.08)($0.09)$1.89 million$1.97 millionViewN/AView Earnings Details
2/24/2016Q4($0.07)($0.07)ViewN/AView Earnings Details
11/2/2015Q315($0.13)($0.14)$1.19 million$1.90 millionViewN/AView Earnings Details
8/10/2015Q2($0.22)($0.11)ViewN/AView Earnings Details
5/7/2015($0.13)($0.10)$0.20 million$0.30 millionViewN/AView Earnings Details
2/26/2015Q414($0.14)($0.09)$420.00 million$0.34 millionViewN/AView Earnings Details
10/30/2014Q314($0.12)($0.06)$3.43 millionViewN/AView Earnings Details
8/7/2014Q214($0.17)($0.06)$7.50 million$0.20 millionViewN/AView Earnings Details
5/8/2014Q114($0.10)($0.10)$0.20 million$0.20 millionViewN/AView Earnings Details
3/3/2014Q413($0.15)($0.09)$0.20 million$0.20 millionViewN/AView Earnings Details
10/22/2013Q313($0.17)($0.20)$0.20 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.24)($0.22)$0.20 million$0.20 millionViewN/AView Earnings Details
3/18/2013Q4 2012($0.29)($0.48)$0.17 million$0.20 millionViewN/AView Earnings Details
11/8/2012Q312($0.28)($0.28)$0.20 million$0.20 millionViewN/AView Earnings Details
8/2/2012($0.23)($0.29)ViewN/AView Earnings Details
5/3/2012($0.22)($0.25)ViewN/AView Earnings Details
2/29/2012($0.23)($0.24)ViewN/AView Earnings Details
11/3/2011($0.28)($0.01)ViewN/AView Earnings Details
8/1/2011($0.23)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ZIOPHARM Oncology (NASDAQ:ZIOP)
Current Year EPS Consensus Estimate: $-0.55 EPS
Next Year EPS Consensus Estimate: $-0.66 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.07)($0.07)($0.07)
Q2 20161($0.12)($0.12)($0.12)
Q3 20161($0.12)($0.12)($0.12)
Q4 20161($0.08)($0.08)($0.08)
Q1 20171($0.09)($0.09)($0.09)
Q2 20171($0.10)($0.10)($0.10)
Q3 20171($0.09)($0.09)($0.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ZIOPHARM Oncology (NASDAQ:ZIOP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ZIOPHARM Oncology (NASDAQ:ZIOP)
Insider Ownership Percentage: 11.50%
Institutional Ownership Percentage: 41.26%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/4/2015Murray BrennanDirectorSell40,000$9.70$388,000.00View SEC Filing  
2/9/2015Randal J KirkDirectorBuy1,440,000$8.75$12,600,000.00View SEC Filing  
10/29/2013Randal J KirkDirectorBuy2,857,143$3.50$10,000,000.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for ZIOPHARM Oncology (NASDAQ:ZIOP)
DateHeadline
capitalcube.com logoZIOPHARM Oncology, Inc. :ZIOP-US: Earnings Analysis: Q4, 2016 By the Numbers : February 22, 2017 (NASDAQ:ZIOP)
www.capitalcube.com - February 23 at 4:12 AM
finance.yahoo.com logoZIOPHARM ONCOLOGY INC Financials (NASDAQ:ZIOP)
finance.yahoo.com - February 23 at 4:12 AM
News IconZIOPHARM Oncology Inc ZIOP Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:ZIOP)
www.bioportfolio.com - February 20 at 8:01 AM
News IconThe Must-Know Technicals As They Stand For ZIOPHARM Oncology, Inc. (ZIOP) - NY Stock News (NASDAQ:ZIOP)
nystocknews.com - February 19 at 8:01 AM
4-traders.com logoZIOPHARM Oncology : reports 4Q loss (NASDAQ:ZIOP)
www.4-traders.com - February 17 at 5:22 PM
investopedia.com logoZiopharm 4Q Loss 11 Cents a Share (ZIOP) (NASDAQ:ZIOP)
www.investopedia.com - February 17 at 5:22 PM
biz.yahoo.com logoZIOPHARM ONCOLOGY INC Files SEC form 10-K, Annual Report (NASDAQ:ZIOP)
us.rd.yahoo.com - February 17 at 5:22 PM
us.rd.yahoo.com logo4:22 pm ZIOPHARM reports Q4 results, provides update on pipeline (NASDAQ:ZIOP)
us.rd.yahoo.com - February 17 at 5:22 PM
investopedia.com logoZiopharm 4Q Loss 11 Cents a Share Vs 7c Last Year (NASDAQ:ZIOP)
www.investopedia.com - February 17 at 5:22 PM
News IconZIOPHARM Oncology, Inc. (ZIOP): How technical signals have emerged? - Post Analyst (NASDAQ:ZIOP)
postanalyst.com - February 17 at 9:25 AM
News IconZIOPHARM Oncology Inc (NASDAQ:ZIOP) Quarterly EPS At $-0.17 - Stock Observer (NASDAQ:ZIOP)
www.thestockobserver.com - February 17 at 9:25 AM
marketexclusive.com logoZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Files An 8-K Results of Operations and Financial Condition - Market Exclusive (NASDAQ:ZIOP)
marketexclusive.com - February 17 at 9:25 AM
sg.finance.yahoo.com logoZiopharm reports 4Q loss (NASDAQ:ZIOP)
sg.finance.yahoo.com - February 17 at 9:25 AM
finance.yahoo.com logo6 Hot Stocks Among Shorts: IBM, Exxon Mobil And More (NASDAQ:ZIOP)
finance.yahoo.com - February 11 at 6:46 AM
smarteranalyst.com logoGriffin Lifts Price Target on ZIOPHARM Oncology Inc. (ZIOP) Ahead of Groundbreaking 2017 (NASDAQ:ZIOP)
www.smarteranalyst.com - February 10 at 6:49 AM
benzinga.com logoAcacia, Exxon And Other Hot Stocks Among Short Sellers (NASDAQ:ZIOP)
www.benzinga.com - February 7 at 4:19 PM
News IconZIOPHARM Oncology Inc (NASDAQ:ZIOP) Upgrades/Downgrades review - The Newburgh Press (NASDAQ:ZIOP)
newburghpress.com - February 2 at 7:00 AM
News IconStock Vacillating as Volatility Hits a High Point For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) - Wall Street Beacon (NASDAQ:ZIOP)
wsbeacon.com - February 1 at 7:39 AM
globenewswire.com logoZIOPHARM Utilizing Non-Viral Sleeping Beauty Platform to Rapidly Produce CAR-Expressing T cells Advancing “Point ... - GlobeNewswire (press release) (NASDAQ:ZIOP)
globenewswire.com - January 31 at 8:17 AM
News IconQuarterly EPS Of ZIOPHARM Oncology Inc (NASDAQ:ZIOP) Set At $-0.17 - Stock Observer (NASDAQ:ZIOP)
www.thestockobserver.com - January 28 at 2:54 AM
News IconAnalyst Research Report on ZIOPHARM Oncology Inc (ZIOP) - Highland Mirror (NASDAQ:ZIOP)
www.highlandmirror.com - January 27 at 6:57 AM
News IconAnalysts Take the Wheel on ZIOPHARM Oncology Inc (NASDAQ:ZIOP) Shares and Where They Might Be Headed - Aiken Advocate (NASDAQ:ZIOP)
aikenadvocate.com - January 24 at 4:02 PM
News IconRent-A-Center, Inc. (NASDAQ:RCII) (NASDAQ:ZIOP)
myhealthbowl.com - January 22 at 8:33 AM
News IconRexahn Pharmaceuticals, Inc. (RNN) Broker Price Targets For The Coming Week (NASDAQ:ZIOP)
baddgoddess.com - January 22 at 8:33 AM
News IconGearing Up For a Bull Run? Analysts Weigh in on ZIOPHARM Oncology Inc (NASDAQ:ZIOP) - Wall Street Beacon (NASDAQ:ZIOP)
wsbeacon.com - January 19 at 9:38 PM
News Icon6 Senators Assessing Trump's HHS Nominee Own Health Care Stocks, Too (NASDAQ:ZIOP)
www.npr.org - January 19 at 8:17 AM
News Icon6 Senators Assessing Trump's HHS Nominee Own Health Care Stocks, Too (NASDAQ:ZIOP)
www.npr.org - January 19 at 8:17 AM
News IconInvestors Priming the Pump as Stock Reaches Most Volatile List: ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) - Wall Street Beacon (NASDAQ:ZIOP)
wsbeacon.com - January 18 at 6:34 AM
News IconWill The Needle Move For ZIOPHARM Oncology Inc (NASDAQ:ZIOP) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:ZIOP)
wsbeacon.com - January 16 at 9:52 PM
News IconZIOPHARM Oncology Inc (ZIOP) stock trades up, "Hold" rating reaffirmed by J P Morgan Chase & Co Analysts - The Ledger Gazette (NASDAQ:ZIOP)
ledgergazette.com - January 15 at 9:40 PM
News IconStocks for Your Case: ZIOPHARM Oncology, Inc. (UTC:ZIOP), Synergy Resources Corporation (NYSEMKT:SYRG) - The Newburgh Press (NASDAQ:ZIOP)
newburghpress.com - January 13 at 3:33 PM
News IconStock Mounting Higher Mid-Session: ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) - Wall Street Beacon (NASDAQ:ZIOP)
wsbeacon.com - January 13 at 7:41 AM
News IconZIOPHARM Oncology Inc (NASDAQ:ZIOP) Quarterly Analysis - The Newburgh Press (NASDAQ:ZIOP)
newburghpress.com - January 13 at 7:41 AM
marketexclusive.com logoHighlighting ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) As A Catalyst Play This Quarter - Market Exclusive (NASDAQ:ZIOP)
marketexclusive.com - January 13 at 7:41 AM
News IconHighlighting ZIOPHARM Oncology Inc. (ZIOP) As A Catalyst Play This Quarter (NASDAQ:ZIOP)
feedproxy.google.com - January 12 at 2:43 PM
4-traders.com logoIntrexon : Announces "When-Issued" Trading of AquaBounty Technologies In Connection With Special Stock Dividend of Shares (NASDAQ:ZIOP)
www.4-traders.com - January 12 at 8:19 AM
4-traders.com logoIntrexon : Announces "When-Issued" Trading of AquaBounty Technologies In Connection With Special Stock Dividend of Shares (NASDAQ:ZIOP)
www.4-traders.com - January 12 at 8:19 AM
reuters.com logoBRIEF-Ziopharm says end of face-to-face meeting with FDA in early Q1 2017 with respect to recurrent Glioblastoma (NASDAQ:ZIOP)
www.reuters.com - January 12 at 8:19 AM
reuters.com logoBRIEF-Ziopharm says end of face-to-face meeting with FDA in early Q1 2017 with respect to recurrent Glioblastoma (NASDAQ:ZIOP)
www.reuters.com - January 12 at 8:19 AM
marketexclusive.com logoHighlighting ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) As A Catalyst Play This Quarter (NASDAQ:ZIOP)
marketexclusive.com - January 12 at 8:19 AM
feeds.benzinga.com logoZiopharm Traders Got A Little Too Excited (NASDAQ:ZIOP)
feeds.benzinga.com - January 11 at 12:51 PM
biz.yahoo.com logoZIOPHARM ONCOLOGY INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:ZIOP)
biz.yahoo.com - January 10 at 9:31 PM
finance.yahoo.com logo8:03 am ZIOPHARM & Intrexon (XON (NASDAQ:ZIOP)
finance.yahoo.com - January 10 at 4:30 PM
benzinga.com logoExclusive: Ziopharm CEO Talks Partnerships, Balance Sheet And JPM Healthcare Conference Presentation - Benzinga (NASDAQ:ZIOP)
www.benzinga.com - January 9 at 3:28 PM
investornewswire.com logoEPS Estimates ZIOPHARM Oncology Inc (NASDAQ:ZIOP) Of At ... - Investor Newswire (NASDAQ:ZIOP)
www.investornewswire.com - January 9 at 5:23 AM
News IconChecking the Levels for ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) - Wall Street Beacon (NASDAQ:ZIOP)
wsbeacon.com - January 9 at 5:23 AM
einnews.com logo(Motor racing) F1 champions Mercedes to 'unveil the beast' on Feb. 23 (NASDAQ:ZIOP)
brazilbusiness.einnews.com - January 5 at 7:45 AM
einnews.com logoSchools to Remain Closed by January 09 (NASDAQ:ZIOP)
brazilbusiness.einnews.com - January 4 at 7:55 AM
zacks.com logoImplied Volatility Surging for ZIOPHARM Oncology (ZIOP) Stock Options (NASDAQ:ZIOP)
www.zacks.com - January 3 at 8:46 AM
News IconDaily Sentiment Score Of ZIOPHARM Oncology Inc (NASDAQ:ZIOP) At 0.095 - Stock Observer (NASDAQ:ZIOP)
www.thestockobserver.com - January 2 at 3:08 AM

Social

What is ZIOPHARM Oncology's stock symbol?

ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."

Where is ZIOPHARM Oncology's stock going? Where will ZIOPHARM Oncology's stock price be in 2017?

5 brokers have issued twelve-month price targets for ZIOPHARM Oncology's shares. Their predictions range from $5.00 to $23.00. On average, they expect ZIOPHARM Oncology's stock price to reach $11.50 in the next year.

When will ZIOPHARM Oncology announce their earnings?

ZIOPHARM Oncology is scheduled to release their next quarterly earnings announcement on Monday, May, 8th 2017.

Who owns ZIOPHARM Oncology stock?

ZIOPHARM Oncology's stock is owned by a number of of institutional and retail investors. Top institutional investors include Third Security LLC (7.44%), State Street Corp (3.08%), MSD Partners L.P. (2.61%), Thrivent Financial for Lutherans (0.11%), Metropolitan Life Insurance Co. NY (0.07%) and Glacier Peak Capital LLC (0.05%).

Who sold ZIOPHARM Oncology stock? Who is selling ZIOPHARM Oncology stock?

ZIOPHARM Oncology's stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Brown Advisory Inc., Private Advisor Group LLC and Metropolitan Life Insurance Co. NY.

Who bought ZIOPHARM Oncology stock? Who is buying ZIOPHARM Oncology stock?

ZIOPHARM Oncology's stock was bought by a variety of institutional investors in the last quarter, including Third Security LLC, Glacier Peak Capital LLC, Michael & Susan Dell Foundation and National Planning Corp.

How do I buy ZIOPHARM Oncology stock?

Shares of ZIOPHARM Oncology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of ZIOPHARM Oncology stock cost?

One share of ZIOPHARM Oncology stock can currently be purchased for approximately $6.21.

ZIOPHARM Oncology (NASDAQ:ZIOP) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)

Earnings History Chart

Earnings by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)

Dividend History Chart

Dividend Payments by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)

Last Updated on 2/23/2017 by MarketBeat.com Staff